Randa Corley
Gerontology · Tuscaloosa, ALNPI 1144946245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $993 and has fallen 71.2% since, to $285 in 2025.
Across 95 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$255
- Otsuka America Pharmaceutical, Inc.$251
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$231
- Amgen$199
- Lilly USA, LLC$185
- Bayer$129
- plus $600 from 16 others
What the payments were for
- Food & beverage$1,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $255 |
| Otsuka America Pharmaceutical, Inc. | 14 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $231 |
| Amgen | 11 | $199 |
| Lilly USA, LLC | 10 | $185 |
| Bayer | 7 | $129 |
| Novo Nordisk | 4 | $73 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| Johnson & Johnson | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Vanda Pharmaceuticals Inc. | 1 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $42 |
| Ardelyx, Inc. | 2 | $34 |
| Exact Sciences | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| GSK | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,851 in reported general payments places this provider in the 70th percentile of 143 gerontology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $86,064 |
| MounjaroTirzepatide | 59 | $74,188 |
| EliquisApixaban | 66 | $56,799 |
| JardianceEmpagliflozin | 43 | $41,681 |
| JanuviaSitagliptin Phosphate | 38 | $36,245 |
| XareltoRivaroxaban | 34 | $34,668 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $31,865 |
| FarxigaDapagliflozin Propanediol | 34 | $29,995 |
| RybelsusSemaglutide | 12 | $27,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $24,797 |
| TrulicityDulaglutide | 11 | $23,862 |
| LinzessLinaclotide | 25 | $23,645 |
| MyrbetriqMirabegron | 32 | $19,873 |
| EntrestoSacubitril/Valsartan | 13 | $10,954 |
| Repatha SureclickEvolocumab | 17 | $9,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $73 | $114,05283 claims |
| Lilly USA, LLCMounjaro, Trulicity | $185 | $98,05070 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $48,03454 claims |
| Johnson & JohnsonXarelto | $67 | $34,66834 claims |
| AstraZenecaFarxiga | $14 | $29,99534 claims |
| GSKTrelegy Ellipta | $21 | $24,79727 claims |
| AbbVieLinzess | $255 | $23,64525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 gerontology providers in Alabama.
Other gerontology in Tuscaloosa
- Ryan ShannonMontgomery$66K
- Claire BruceHuntsville$12K
- Michelle SanfordMobile$11K
- Virginia McNeillNorthport$11K
- Esther LangeBirmingham$10K
- Sari CapiloutoMontgomery$9K
- Melissa WatkinsDothan$8K
- Melissa HornBirmingham$7K
- Rachel HawesBirmingham$7K
- Stephanie FoutsMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.